SOURCE: Industrial Info Resources

October 16, 2008 06:30 ET

Genentech Raises Quarterly Profits With Increased Sales of Anti-Cancer Drugs, an Industrial Info News Alert

SUGAR LAND, TX--(Marketwire - October 16, 2008) - Researched by Industrial Info Resources (Sugar Land, Texas) -- Genentech Incorporated (NYSE:DNA) (South San Francisco, California), one of the world's leading biotechnology companies, released its third quarter profits for 2008 on Tuesday, October 14. Genentech's net income was $731 million, an increase of 7% from last year's third quarter, which brought a net income of $685 million. Sales of the company's flagship oncology drug Avastin, used to inhibit the growth of tumors in colon, lung and breast cancers, were up 18% from 3Q07. Swiss-based pharmaceutical giant Roche Holdings Limited (PINKSHEETS:RHHBY) (Basel) currently holds about 56% of Genentech's shares and made a proposal to purchase the remaining Genentech shares in July.

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at, or browse other breaking industrial news stories at

Industrial Info Resources (IIR) is a marketing information service specializing in industrial process, energy and financial related markets with products and services ranging from industry news, analytics, forecasting, plant and project databases, as well as multimedia services. For more information send inquiries to or visit us at

Related News Articles

UT Health Science Center at Houston Invests $161.5 Million for Construction of Research Park Complex

Bubbles, Bailouts, Bears and Biotech

Show Me the Salmonella! Safety Concerns Spur FDA to Invest $2.5 Billion to Upgrade Tracking Technology

Contact Information

  • Contact:
    Joe Govreau